v3.20.4
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Revenue $ 7,649 $ 7,159 $ 23,319 $ 23,730
Cost of revenue 5,443 4,379 15,480 16,125
Gross profit 2,206 2,780 7,839 7,605
Operating expenses        
Research and development 1,006 1,222 2,865 4,227
Sales and marketing 1,200 1,556 4,024 6,147
General and administrative 863 1,093 3,175 3,706
Intangible amortization 226 308 677 924
Restructuring Charges 0 234 0 234
Total operating expenses 3,295 4,413 10,741 15,238
Operating profit (loss) (1,089) (1,633) (2,902) (7,633)
Other income, net 178 109 223 398
Income (loss) before income taxes (911) (1,524) (2,679) (7,235)
Income tax benefit (expense) (23) (20) 35 (27)
Net income (loss) (1) [1] $ (934) $ (1,544) $ (2,644) $ (7,262)
Basic $ (0.09) $ (0.10) $ (0.19) $ (0.47)
Diluted $ (0.09) $ (0.10) $ (0.19) $ (0.47)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 700 1,000 800 900
Weighted-average number of common shares outstanding:        
Basic (shares) 10,984 15,575 14,125 15,514
Effect of dilutive securities: restricted stock, restricted stock units, performance stock units and stock options (2) [2] 0 0 0 0
Diluted (shares) 10,984 15,575 14,125 15,514
[1] Net income (loss) and comprehensive income (loss) are the same for the periods reported.
[2] The Company had 0.7 million shares and 0.8 million shares, represented by common stock equivalents for the three and nine months ended December 31, 2020, and 1.0 million shares and 0.9 million shares for the three and nine months ended December 31, 2019, respectively, which were not included in the computation of average dilutive shares outstanding because they were anti-dilutive. In periods with a net loss from continuing operations, the basic loss per share equals the diluted loss per share as all common stock equivalents are excluded from the per share calculation.

Source